| GR00018-A-0 | 283106 | | CSNK2A1 | v2HS_150988 | -1.56 (0.23) | Synthetic lethal with Ras | | no | | Synthetic lethal interaction with Ras | A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. | Luo et al. | 2009 | 19490893 | Cell line | DLD-1 | Synthetic lethal interaction with Ras | Micoarray hybridization | shRNA-mir (G. Hannon) | | shRNA | Log2 diff MUT-WT (and P-value) | -0.7 (0.3) | | GR00057-A-1 | 283106 | NM_001895 | CSNK2A1 | M-003475-00 | -0.42 | none | | no | | Wnt/beta-catenin pathway regulation (1) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Z-score | > 4 | Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-2 | 283106 | NM_001895 | CSNK2A1 | M-003475-00 | sp | none | | no | | Wnt/beta-catenin pathway regulation (2) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Complex, SP | Complex criteria | Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00184-A-1 | 283106 | NM_001895 | CSNK2A1 | M-003475-00 | -0.829463233953958 | none | | no | | Self-renewal and pluripotency in human embryonic stem cells (1) | A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. | Chia et al. | 2010 | 20953172 | Cell line | hESC H1 | POU5F1 protein expression | Fluorescence | SMARTpool siRNA library | Genome-wide | siRNA | Z-score | < -2 | | GR00197-A-1 | 283106 | 1457 | CSNK2A1 | M-003475-00 | 1.305663801 | none | | no | | Human papillomavirus oncogene expression regulation (1) | Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. | Smith et al. | 2010 | 20133580 | Cell line | C33A/BE2/18LCR c4 | HPV18 LCR reporter activity | Luminescence | Human siGENOME SMARTpool library | Genome-wide | siRNA | Z-score | > | Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 | GR00221-A-1 | 283106 | | CSNK2A1 | TRCN0000000608 | 2.45 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-1 | 283106 | | CSNK2A1 | TRCN0000000610 | 3.55 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-1 | 283106 | | CSNK2A1 | TRCN0000000607 | -1.22 | Decreased viability | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-1 | 283106 | | CSNK2A1 | TRCN0000001987 | 0.34 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-1 | 283106 | | CSNK2A1 | TRCN0000001985 | 1.65 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 283106 | | CSNK2A1 | TRCN0000000609 | -3.26 | Decreased viability | | yes | essential gene | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 283106 | | CSNK2A1 | TRCN0000000607 | -1.54 | Decreased viability | | yes | essential gene | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 283106 | | CSNK2A1 | TRCN0000001987 | -0.34 | none | | yes | essential gene | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 283106 | | CSNK2A1 | TRCN0000000610 | 1.04 | none | | yes | essential gene | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 283106 | | CSNK2A1 | TRCN0000001985 | 1.12 | none | | yes | essential gene | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 283106 | | CSNK2A1 | TRCN0000000608 | 1.92 | none | | yes | essential gene | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 283106 | | CSNK2A1 | TRCN0000001985 | -0.77 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 283106 | | CSNK2A1 | TRCN0000001987 | -0.61 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 283106 | | CSNK2A1 | TRCN0000000607 | -0.48 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 283106 | | CSNK2A1 | TRCN0000000610 | -0.24 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 283106 | | CSNK2A1 | TRCN0000000608 | 0.54 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 283106 | | CSNK2A1 | TRCN0000000607 | -0.03 | none | | no | | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 283106 | | CSNK2A1 | TRCN0000001987 | 0.25 | none | | no | | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 283106 | | CSNK2A1 | TRCN0000001985 | 1.02 | none | | no | | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 283106 | | CSNK2A1 | TRCN0000000610 | 1.58 | none | | no | | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 283106 | | CSNK2A1 | TRCN0000000608 | 1.78 | none | | no | | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00231-A | 283106 | NM_001895 | CSNK2A1 | M-003475-00 | -0.238 | none | | yes | | Cell proliferation | Time-resolved human kinome RNAi screen identifies a network regulating mitotic-events as early regulators of cell proliferation. | Zhang et al. | 2011 | 21765947 | Cell line | HeLa | Viability | Electrical impedance | Human siARRAY - Protein Kinase and Cell Cycle libraries | Kinases and selected genes | siRNA | Z-score | < -1.96 OR > 1.96 | Additional information about cell titer blue cell viability screen | GR00236-A-1 | 283106 | 1457 | CSNK2A1 | M-003475-00 | 2.06170700850036 | Increased homologous recombination repair frequency | | yes | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Human siGENOME siRNA (G-005000-05) | Genome-wide | siRNA | Relative HR ratio | < ~0.4 OR > 1.88 | Cutoff values correspond 2 standard deviations from the screen-wide mean | | 283106 | 1457 | CSNK2A1 | D-003475-01 | 1.03 | none | | no | | | | | | | | | | | | | | | | | | 283106 | 1457 | CSNK2A1 | D-003475-02 | 1.59 | none | | no | | | | | | | | | | | | | | | | | | 283106 | 1457 | CSNK2A1 | D-003475-03 | 1.01 | none | | no | | | | | | | | | | | | | | | | | | 283106 | 1457 | CSNK2A1 | D-003475-04 | 2.33 | Increased homologous recombination repair frequency | | no | strong cutoff | | | | | | | | | | | | | | | | GR00240-S-1 | 283106 | NM_001895 | CSNK2A1 | M-003475-00 | -0.05 | none | | yes | | TRAIL-induced apoptosis (1) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Z-score | > 4 | Author-submitted data | GR00240-S-2 | 283106 | NM_001895 | CSNK2A1 | M-003475-00 | 0.68 | none | | no | Z-score 0.7705 | TRAIL-induced apoptosis (2) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability (synthetic lethal) | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Differential score | > 3.6 AND viability Z-score < 4 | Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. | GR00249-S | 283106 | 1457 | CSNK2A1 | s3636 | -1.47286 | none | | no | number of cells compared to control (%): 77.09 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 283106 | 1457 | CSNK2A1 | s3637 | 0.30045 | none | | no | number of cells compared to control (%): 93.39 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 283106 | 1457 | CSNK2A1 | s3638 | -1.10335 | none | | no | number of cells compared to control (%): 88.91 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00250-A-1 | 283106 | 1457 | CSNK2A1 | M-003475-00 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (1) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Genome-wide | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 283106 | 1457 | CSNK2A1 | D-003475-01 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 283106 | 1457 | CSNK2A1 | D-003475-02 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 283106 | 1457 | CSNK2A1 | D-003475-03 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 283106 | 1457 | CSNK2A1 | D-003475-04 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00255-A-1 | 283106 | 1457 | CSNK2A1 | TRCN0000000606, TRCN0000000608, TRCN0000000609, TRCN0000001987, TRCN0000010673 | -0.601431225 | none | | | | Negative genetic interactions (1) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-2 | 283106 | 1457 | CSNK2A1 | TRCN0000000606, TRCN0000000608, TRCN0000000609, TRCN0000001987, TRCN0000010673 | -0.10230006 | none | | | | Negative genetic interactions (2) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-3 | 283106 | 1457 | CSNK2A1 | TRCN0000000606, TRCN0000000608, TRCN0000000609, TRCN0000001987, TRCN0000010673 | -0.451135053 | none | | | | Negative genetic interactions (3) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-4 | 283106 | 1457 | CSNK2A1 | TRCN0000000606, TRCN0000000608, TRCN0000000609, TRCN0000001987, TRCN0000010673 | 0.059285222 | none | | | | Negative genetic interactions (4) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-5 | 283106 | 1457 | CSNK2A1 | TRCN0000000606, TRCN0000000608, TRCN0000000609, TRCN0000001987, TRCN0000010673 | -0.018793046 | none | | | | Negative genetic interactions (5) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -0.8 | HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00327-A | 283106 | 1458 | FZD3 | CLL-H-010604 | 0.8227037036917796 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 283106 | 1458 | FZD3 | CLL-H-010609 | -1.3226827378311128 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 283106 | 1458 | FZD3 | CLL-H-010607 | 0.9276120538859035 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 283106 | 1458 | FZD3 | CLL-H-010605 | -0.19950566299411082 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 283106 | 1458 | FZD3 | CLL-H-010608 | -0.9701617483497776 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 283106 | 1458 | FZD3 | CLL-H-010606 | -0.159721083532173 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00342-S-1 | 283106 | | CSNK2A1 | M-003475-00 | 0.008221485664018965 | none | | | | Viability of Mesenchymal Stem Cells (MSC) (1) | Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening | Erdmann et al. | 2015 | 26120366 | Primary cells | Bone marrow derived MSC | Viability | Luminescence | Kinase siGENOME SMARTpool library | Kinases and phosphatases | siRNA | Z-score | > | Donor 1, MSC preparation 1 (MSC1a) | GR00342-S-2 | 283106 | | CSNK2A1 | M-003475-00 | -0.279410898719174 | none | | | | Viability of Mesenchymal Stem Cells (MSC) (2) | Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening | Erdmann et al. | 2015 | 26120366 | Primary cells | Bone marrow derived MSC | Viability | Luminescence | Kinase siGENOME SMARTpool library | Kinases and phosphatases | siRNA | Z-score | > | Donor 1, MSC preparation 2 (MSC1b) | GR00342-S-3 | 283106 | | CSNK2A1 | M-003475-00 | 0.4296651291188026 | none | | | | Viability of Mesenchymal Stem Cells (MSC) (3) | Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening | Erdmann et al. | 2015 | 26120366 | Primary cells | Bone marrow derived MSC | Viability | Luminescence | Kinase siGENOME SMARTpool library | Kinases and phosphatases | siRNA | Z-score | > | Donor 2, MSC preparation 1 (MSC2) | GR00343-S | 283106 | 1457 | CSNK2A1 | TRCN0000000608 | 1.052500000000002 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 283106 | 1457 | CSNK2A1 | TRCN0000000607 | 0.197499999999998 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 283106 | 1457 | CSNK2A1 | TRCN0000000609 | 0.21749999999999936 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 283106 | 1457 | CSNK2A1 | TRCN0000000610 | 0.9599999999999991 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | | 283106 | NM_001895 | CSNK2A1 | M-003475-00 | 2.2 | Decreased Dengue Infection | | | 4.61 | | | | | | | | | | | | | | | | | 283106 | NM_001895 | CSNK2A1 | M-003475-00 | 3.01 | Decreased infection with West Nile virus (WNV) | | | 3.8 | | | | | | | | | | | | | | | | | 283106 | CSNK2A1 | NM_001895 | D-003475-04 | 2.8 | Decreased West Nile virus (WNV) infection | | | 3.6 | | | | | | | | | | | | | | | | | 283106 | CSNK2A1 | NM_001895 | D-003475-03 | 2.3 | Decreased West Nile virus (WNV) infection | | | 3.31 | | | | | | | | | | | | | | | | | 283106 | CSNK2A1 | NM_001895 | D-003475-01 | 3.2 | Decreased West Nile virus (WNV) infection | | | 4.1 | | | | | | | | | | | | | | | |